Back to Research Home
EGRXEagle Pharmaceuticals Inc
Health Care · Pharmaceuticals
$1.00−74.59%
As of 23 Oct 2026Mkt cap —
Stage 13
WAIT
Fundamentals
—/75
Technical
—/15
Independent
—/90
GCAE viewtechnical state requires waiting rather than entering now
Price
- 1M
- +850.6%
- 3M
- +412.7%
- 6M
- −68.8%
- 1Y
- +53.8%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- —
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- —
- FCF yield
- —
Quality
- ROIC
- 26.7%
- Operating margin
- 17.5%
- FCF margin
- 16.0%
- Current ratio
- 1.7x
Growth
- Revenue growth
- +84.6%Latest FY YoY
- Revenue CAGR
- +10.4%
- EPS CAGR
- +6.9%
- FCF CAGR
- −0.8%
Capital
- Share-count trend
- −2.6%3Y annualised
- Net debt
- $10M0.2x OCF
Annual trend
- CAGR 2018–2022
- +10.4%
- Latest · 2022
- $0B
- YoY
- +84.6%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
technical state requires waiting rather than entering now
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
More details & evidence
Production decision
- Stage 13
- WAIT
- Technical state
- insufficient-data
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded